E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
ER+, HER2- early breast cancer |
|
E.1.1.1 | Medical condition in easily understood language |
Potentially curable breast cancer which is positive for oestrogen receptor expression and negative for HER2 expression |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057654 |
E.1.2 | Term | Breast cancer female |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The principal research question of the UNIRAD trial is: when everolimus treatment is given to breast cancer patients in addition to their standard care, is the chance of their cancer returning reduced in comparison to patients who did not receive everolimus treatment? |
|
E.2.2 | Secondary objectives of the trial |
The secondary research questions of the UNIRAD trial include: when everolimus treatment is given to breast cancer patients in addition to standard care: - do patients live longer than patients who did not receive everolimus treatment? - is there a certain group of patients who benefit the most from everolimus treatment (both in terms of their cancer returning and how long they live)? - is everolimus treatment safe and tolerable for the patients participating in the UNIRAD trial? - what can be learned from the biology of the patients' tumour tissue - are there biological markers that identify the patients who benefit most from everolimus treatment? - is the quality of life of patients who receive everolimus treatment the same as patients who did not receive everolimus treatment? |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
The UNIRAD protocol contains details of two planned sub-studies which are considered integral to the trial design (as they are contained in the protocol, no seperate version numbers are provided):
- Quality of Life (EORTC QLQ-C30) Patients will complete quality of life questionnaires every 4 months while they are receiving trial treatment. The quality of life of patients who received everolimus will be compared to the quality of life of those who did not.
- Translational sub-studies A number of exploratory analyses are planned using tumour and blood samples collected from patients participating in the trial. The aim of these studies will be to investigate which patients are at the highest risk of disease relapse and which patients are most likely to respond to everolimus treatment. A translational sub-study led in the UK will also investigate whether DNA extracted from plasma blood samples (cell free DNA or cfDNA) can be used to determine which patients will respond to treatment and those who are at the highest risk of disease relapse. The collection of blood samples is much less invasive than the collection of tumour tissue, and as such if blood samples are able to provide information which currently is only available from tumour tissue, this will be very important for future research and treatment. |
|
E.3 | Principal inclusion criteria |
1. Female ≥ 18 years of age 2. Histologically proven invasive unilateral or bilateral breast cancer (regardless of the morphological subtype) 3. Any T, M0 (according to the American Joint Committee on Cancer classification) 4. At least 4 positive lymph nodes if the patient had primary surgery, or at least 1 positive lymph node if surgery was conducted after neo-adjuvant chemotherapy or hormone therapy of at least 3 months duration 5. ER+ and HER2 negative : Hormone receptor positive is defined as any staining on the primary tumor, HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH non-amplified] 6. Primary tumor completely resected (deep margins and overlying skin involvement allowed if fully resected) 7. Patients who have received at least 1 year but not more than 4 years of adjuvant hormone therapy. Hormone therapy could be either tamoxifen, letrozole, anastrozole or exemestane. 8. No clinically or radiologically detectable metastases at time of inclusion. 9. WHO Performance status (ECOG) of 0 or 1. 10. Adequate hematological function (neutrophil count 2x109/l, platelet count 100x 109/l) 11. Adequate hepatic function: AST and ALT ≤ 2.5 ULN, alkaline phosphatases ≤ 2.5 ULN, total bilirubin ≤ 2 ULN. 12. Adequate renal function: serum creatinine ≤ 1.5 ULN. 13. Signed written informed consent. |
|
E.4 | Principal exclusion criteria |
1. Any local, or regional recurrence or metastatic disease. 2. Any clinical or radiological suspicion of malignant or pre-malignant disease in the contralateral breast. 3. Previous cancer (excepted basal cell carcinoma of the skin or in situ carcinoma of the cervix) in the preceding 5 years, including invasive contralateral breast cancer. 4. Patient already included in another ongoing therapeutic trial involving an unlicensed drug for which follow-up is required. 5. Patient who is pregnant or breast-feeding. Adequate birth control measures should be taken during the study treatment phase. 6. Patient with significantly impaired lung function (e.g. Chronic Obstructive Pulmonary Disease, respiratory insufficiency, Interstitial Lung Disease) 7. Positive serology for HIV infection or hepatitis C. 8. Chronic carrier of HBV (positive Antigen HbsAg positive HbS in the blood) 9. Patient with chronic infection 10. Uncontrolled diabetes defined as glycated haemoglobinemia , HbA1c>7% 11. Uncontrolled hypercholesterolemia (cholesterol >300 mg/dl under adequate therapy). 12. Known hypersensitivity to the active substance, to other rapamycin derivatives or to any of the excipients. 13. Patient with other concurrent severe and/or uncontrolled medical disease or infection which could compromise participation in the study (e.g. patient who regularly require systemic steroids to control co-morbid disease). 14. Patient with any psychological, familial, social or geographical condition which could potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. 15. Patients with pN1mi as sole nodal involvement |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Disease free survival rate (DFS) after randomization (disease is defined as local, regional or metastatic relapse, a new contralateral breast cancer, or death from any cause).
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Disease Free Survival will be calculated from randomization date to first occurrence of breast cancer relapse (local, regional or distant) or to the date of invasive contralateral breast cancer or death from any cause, whichever occurs first or to date of last visit (censured data). |
|
E.5.2 | Secondary end point(s) |
1) Efficacy: - Assessment of impact of everolimus on the overall survival (OS), the Event Free Survival (EFS), Distant Metastasis Free Survival (DMFS) and Bone Metastatic Free survival (BMFS) - Assessment of impact of everolimus on DFS and OS in ER+,PR+ and ER+/PR subgroups - Impact of everolimus on the incidence of secondary cancers
2) Toxicity: - Assessment of the safety profile of everolimus in combination with hormone therapy.
3) Biological: - Predictive value of mTOR activation markers on DFS: IHC analysis of primary tumor for pS6K and p4EBP. - Other translational analyses linking cancer biology with outcomes
4) Quality of life sub-studies
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) Efficacy will be assessed for at least 15 years after the end of study (time from when last patient has completed their 5 year follow up)
2) Toxicity will be assessed for a total of 7 years (2 years whilst the patient is on study treatment, 5 years during follow up) YYear 1 - at month 1, month 2, month 3, month 4, month 8, month 12 Year 2 - month 16, month 20, month 24 Year 3 - every 6 months Year 4 - every 6 months Year 5 - yearly Year 6 - yearly Year 7 - yearly
3) Biological - samples will be stored indefinately, destroyed after use or returned to the donors hospital, no time point is specified for the analysis of these
4) Quality of life will be assessed for the 2 years the patient is on trial treatment at baseline, M1, M4, M8, M12, M16, M20, M24. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 23 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 88 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Date of last data capture for the last patient. These breast cancer patients remain at risk of relapse for at least another 10 years so long-term follow-up is important for efficacy reasons, and for safety reasons we need to understand any possible late effects from the use of everolimus. Patients will actively be followed up (seen in clinic) for 5 years post trial treatment. They will then be followed up by tracking of their medical records. Patients consent for this will be sought.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 16 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 16 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |